Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lara Felicioni

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Oncotarget|December 21, 2019
An innovative diagnostic strategy for the detection of rare molecular targets to select cancer patients for tumor-agnostic treatmentsAntonio Marchetti, Alessia Di Lorito, Lara Felicioni, et al.
Human Pathology|September 6, 2023
Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumorEmanuela D'Angelo, Iñigo Espinosa, Lara Felicioni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2011
Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutationsAntonio Marchetti, Lara Felicioni, Sara Malatesta, et al.
The Journal of Clinical Investigation|October 20, 2007
Survival prediction of stage I lung adenocarcinomas by expression of 10 genesFabrizio Bianchi, Paolo Nuciforo, Manuela Vecchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2007
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomasMattia Barbareschi, Fiamma Buttitta, Lara Felicioni, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 27, 2016
ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing AlgorithmAntonio Marchetti, Alessia Di Lorito, Maria Vittoria Pace, et al.
The Journal of Pathology|December 15, 2005
PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinomaFiamma Buttitta, Lara Felicioni, Fabio Barassi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinomaFiamma Buttitta, Caterina Pellegrini, Antonio Marchetti, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2016
Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: Comparison with FISH, immunohistochemistry and next generation sequencing assaysAntonio Marchetti, Maria Vittoria Pace, Alessia Di Lorito, et al.
Plos One|September 1, 2009
Mutational profile of GNAQQ209 in human tumorsSimona Lamba, Lara Felicioni, Fiamma Buttitta, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Oncotarget|December 21, 2019
An innovative diagnostic strategy for the detection of rare molecular targets to select cancer patients for tumor-agnostic treatmentsAntonio Marchetti, Alessia Di Lorito, Lara Felicioni, et al.
Human Pathology|September 6, 2023
Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumorEmanuela D'Angelo, Iñigo Espinosa, Lara Felicioni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2011
Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutationsAntonio Marchetti, Lara Felicioni, Sara Malatesta, et al.
The Journal of Clinical Investigation|October 20, 2007
Survival prediction of stage I lung adenocarcinomas by expression of 10 genesFabrizio Bianchi, Paolo Nuciforo, Manuela Vecchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2007
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomasMattia Barbareschi, Fiamma Buttitta, Lara Felicioni, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 27, 2016
ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing AlgorithmAntonio Marchetti, Alessia Di Lorito, Maria Vittoria Pace, et al.
The Journal of Pathology|December 15, 2005
PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinomaFiamma Buttitta, Lara Felicioni, Fabio Barassi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinomaFiamma Buttitta, Caterina Pellegrini, Antonio Marchetti, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2016
Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: Comparison with FISH, immunohistochemistry and next generation sequencing assaysAntonio Marchetti, Maria Vittoria Pace, Alessia Di Lorito, et al.
Plos One|September 1, 2009
Mutational profile of GNAQQ209 in human tumorsSimona Lamba, Lara Felicioni, Fiamma Buttitta, et al.
Pageof 4